Prima BioMed (IMMP) Stock Price, News & Analysis

Company Overview

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Key Stats

• Today's Range: $1.70 to $1.74
• 50-Day Range: $1.52 to $2.49
• 52-Week Range: $1.32 to $2.72
• Volume: 16,498 shs
• Average Volume: 192,014 shs
• Market Capitalization: $249.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

Prima BioMed Stock Analysis - MarketRank™

Prima BioMed scored higher than 20% of companies evaluated by MarketBeat, and ranked 852nd out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Prima BioMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Prima BioMed has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Prima BioMed are expected to decrease in the coming year, from ($0.40) to ($0.50) per share.

Price to Book Value per Share Ratio

Prima BioMed has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.96% of the float of Prima BioMed has been sold short.

Short Interest Ratio / Days to Cover

Prima BioMed has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Prima BioMed has recently increased by 1.21%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Prima BioMed does not currently pay a dividend.

Dividend Growth

Prima BioMed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.96% of the float of Prima BioMed has been sold short.

Short Interest Ratio / Days to Cover

Prima BioMed has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Prima BioMed has recently increased by 1.21%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for IMMP on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Prima BioMed to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Prima BioMed insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.07% of the stock of Prima BioMed is held by insiders.

Percentage Held by Institutions

Only 2.32% of the stock of Prima BioMed is held by institutions.

IMMP Stock Analysis - Frequently Asked Questions

How have IMMP shares performed this year?

Prima BioMed's stock was trading at $2.17 at the start of the year. Since then, IMMP stock has decreased by 21.2% and is now trading at $1.71.

How do I buy shares of Prima BioMed?

Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Prima BioMed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Prima BioMed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Pfizer (PFE), Broadcom (AVGO) and GE Aerospace (GE).

Company Calendar

• Today: 7/05/2025
• Next Earnings (Estimated): 7/29/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMMP
• CIK: 1506184
• Web: www.immutep.com
• Phone: (128) 315-7003
• Fax: 61-2-8569-1880
• Employees: 2,021
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.00
• High Stock Price Target: $7.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +309.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.86
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $5.14 million
• Price / Sales: 48.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.05 per share
• Price / Book: 1.63

Miscellaneous

• Outstanding Shares: 146,040,000
• Free Float: 141,556,000
• Market Cap: $249.73 million
• Optionable: Optionable
• Beta: 1.71